Indications for: LOTEMAX SM
Post-op inflammation and pain after ocular surgery.
The efficacy of Lotemax SM was evaluated in 2 randomized, multicenter, double-masked, parallel-group, vehicle-controlled studies in patients who underwent cataract extraction with intraocular lens implantation. Patients were randomly assigned to receive either Lotemax SM or vehicle three times daily to the affected eye starting the day after cataract surgery.
Lotemax SM was more effective in resolving anterior chamber inflammation and pain following surgery compared with vehicle.
At post-operative Day 8, Lotemax achieved a statistically significant higher rate of patients with complete clearing of anterior chamber cells and patients who were pain-free.
1 drop into operated eye(s) 3 times daily beginning 24hrs after surgery, continue for 2wks post-op.
LOTEMAX SM Contraindications:
Ocular fungal, viral, or mycobacterial infections.
LOTEMAX SM Warnings/Precautions:
Reevaluate if no improvement after 2 days. Prescribe initially and renew only after appropriate exam. Corneal or scleral thinning. Glaucoma. History of herpes simplex. Monitor IOP and for secondary infections in prolonged therapy (>10 days). Avoid abrupt cessation. Contact lenses (remove during therapy and when eyes are inflamed). Pregnancy. Nursing mothers.
LOTEMAX SM Classification:
Local reactions (eg, blurred vision, burning, itching, dry eye), photophobia, headache, rhinitis, pharyngitis. May mask or exacerbate ocular infections. Prolonged use may increase: IOP, optic nerve damage, visual acuity and field defects, cataract formation, corneal perforation. May delay healing and increase bleb formation after cataract surgery; also, Oint/Gel: anterior chamber inflammation, conjunctival hyperemia, corneal edema, eye pain.
Susp—5mL, 10mL, 15mL, Oint—3.5g; Gel—5g